Breast Cancer

What are the most influential patient characteristics on payer management of breast cancer?
Extensive payer feedback to the latest clinical data of pipeline agents trastuzumab-DM1, neratinib, pertuzumab, eribulin and denosumab
Where do payers expect the pipeline agents to fit in the treatment paradigm?
How many plans require HER2 testing for newly diagnosed patients?
How are plans managing Herceptin in the neo-adjuvant setting for HER2+ breast cancer?
How are plans managing the combination use of Herceptin and Tykerb for HER+ patients?
What kind of improvement in OS for Herceptin/Tykerb combination over lapatinib are payers looking for?
How many plans cover the use of Avastin in breast cancer?